| Active substance | odevixibat |
| Holder | Tanner Pharma |
| Status | Running |
| Indication | treatment of cholestatic liver disease in patients with Alagille Syndrome |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 12/01/2024 |